TITLE

CNE/CME questions

PUB. DATE
December 2009
SOURCE
AIDS Alert;Dec2009, Vol. 24 Issue 12, p143
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
48623528

 

Related Articles

  • HIV treatment costs balloon for clinics as funding remains flat.  // AIDS Alert;Apr2009, Vol. 24 Issue 4, p37 

    The article reports that HIV treatment costs will continue to increase if funding for HIV clinics remains stable in the U.S.

  • HIV doc shortage may block access to care.  // Hospice Management Advisor;Feb2009, Vol. 14 Issue 2, p20 

    The article focuses on the potential problem brought by the shortage of HIV doctors in the medical industry. A recent study conducted by the HIV Medicine Association (HIVMA) shows that the recruitment of HIV physicians is very difficult for the health sectors. It also provides a discussion on...

  • A New Class of Anti-HIV Therapy and New Challenges. Dolin, Raphael // New England Journal of Medicine;10/2/2008, Vol. 359 Issue 14, p1509 

    The author reflects on several new drugs, including maraviroc, which have been developed to treat the HIV-1 virus. He suggests that the development has led to a combination therapy that can inhibit various steps of the virus' replication. He argues that the availability of a new class of...

  • Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. Bozzette, Samuel A.; Joyce, Geoffrey; McCaffrey, Daniel F.; Leibowitz, Arleen A.; Morton, Sally C.; Berry, Sandra H.; Rastegar, Afshin; Timberlake, David; Shapiro, Martin F.; Goldman, Dana P. // New England Journal of Medicine;03/15/2001, Vol. 344 Issue 11, p817 

    Background: The introduction of expensive but very effective antiviral medications has led to questions about the effects on the total use of resources for the care of patients with human immunodeficiency virus (HIV) infection. We examined expenditures for the care of HIV-infected patients since...

  • The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. Freedberg, Kenneth A.; Losina, Elena; Weinstein, Milton C.; Paltiel, A. David; Cohen, Calvin J.; Seage, George R.; Craven, Donald E.; Zhang, Hong; Kimmel, April D.; Goldie, Sue J. // New England Journal of Medicine;03/15/2001, Vol. 344 Issue 11, p824 

    Background: Combination antiretroviral therapy with a combination of three or more drugs has become the standard of care for patients with human immunodeficiency virus (HIV) infection in the United States. We estimated the clinical benefits and cost effectiveness of three-drug antiretroviral...

  • Providing Antiretroviral Therapy for HIV Infection. Steinbrook, Robert // New England Journal of Medicine;03/15/2001, Vol. 344 Issue 11, p844 

    Editorial. Focuses on the cost of combination antiretroviral therapy for HIV infection. Two reports in the March 15, 2001 issue of 'The New England Journal of Medicine,' which provide compelling evidence of the overall value of antiretroviral therapy; How the studies highlight the fragmented...

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. Gulick, Roy M.; Lalezari, Jacob; Goodrich, James; Clumeck, Nathan; DeJesus, Edwin; Horban, Andrzej; Nadler, Jeffrey; Clotet, Bonaventura; Karlsson, Anders; Wohlfeiler, Michael; Montana, John B.; McHale, Mary; Sullivan, John; Ridgway, Caroline; Felstead, Steve; Dunne, Michael W.; van der Ryst, Elna; Mayer, Howard // New England Journal of Medicine;10/2/2008, Vol. 359 Issue 14, p1429 

    Background: CC chemokine receptor 5 antagonists are a new class of antiretroviral agents. Methods: We conducted two double-blind, placebo-controlled, phase 3 studies � Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2...

  • Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. F�tkenheuer, Gerd; Nelson, Mark; Lazzarin, Adriano; Konourina, Irina; Hoepelman, Andy I.M.; Lampiris, Harry; Hirschel, Bernard; Tebas, Pablo; Raffi, Fran�ois; Trottier, Benoit; Bellos, Nicholaos; Saag, Michael; Cooper, David A.; Westby, Mike; Tawadrous, Margaret; Sullivan, John F.; Ridgway, Caroline; Dunne, Michael W.; Felstead, Steve; Mayer, Howard // New England Journal of Medicine;10/2/2008, Vol. 359 Issue 14, p1442 

    Background: We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients. Methods:...

  • Effect of Immunization with a Common Recall Antigen on Viral Expression in Patients Infected with Human Immunodeficiency Virus Type 1.  // New England Journal of Medicine;8/22/96, Vol. 335 Issue 8, p607 

    A correction to the article "Effect of Immunization with a Common Recall Antigen on Viral Expression in Patients Infected with Human Immunodeficiency Virus Type 1" that was published in the May 9, 1996 issue is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics